Waldenström macroglobulinemia : Japanese perception

Waldenström macroglobulinemia (WM) is a rare low-grade B-cell lymphoma. This report focuses on WM in Japan. Regarding epidemiology, per the 2016 registry data by the Japanese Society of Hematology, WM and lymphoplasmacytic lymphoma (LPL) cases were 229 and 125, respectively (1.97% of 17,957 mature lymphoid malignancies), with the annual incidence of WM/LPL in Japan 2.8 per million. In addition, 6q deletion (6q del) is the leading aberration and one of the poor prognostic factors in WM. Our findings suggested that the serum IgM level was higher in WM with 6q del compared with those without, and the B-cell receptor signaling pathway and IL-21 receptor expression were activated in WM with 6q del. Hence, these findings might be attributed to the aggressiveness of the WM with 6q del. Regarding treatment, recent studies investigating the epidemiological treatment pattern for WM have reported rituximab (R) monotherapy and alkylating regimen (±R) as the leading initial treatment. Nevertheless, ideal treatment algorithm in Japan warrants further investigation.

Medienart:

E-Artikel

Erscheinungsjahr:

2019

Erschienen:

2019

Enthalten in:

Zur Gesamtaufnahme - volume:60

Enthalten in:

Rinsho ketsueki] The Japanese journal of clinical hematology - 60(2019), 8 vom: 27., Seite 988-997

Sprache:

Japanisch

Beteiligte Personen:

Sekiguchi, Naohiro [VerfasserIn]

Links:

Volltext

Themen:

Annual incidence
B-cell receptor signaling pathway
Chromosome 6q deletion
Journal Article
Waldenström macroglobuminemia

Anmerkungen:

Date Completed 10.09.2019

Date Revised 10.09.2019

published: Print

Citation Status MEDLINE

doi:

10.11406/rinketsu.60.988

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM300939582